BMJ Retracts Stem Cell Heart Trial After Investigation, Data Integrity Concerns Referred to Iran FDA

The BMJ has formally retracted a high-profile phase 3 clinical trial on stem cell therapy for heart failure after concluding an investigation into serious concerns about the study's reliability and data integrity. The journal's action follows an expression of concern issued in late 2025, triggered by post-publication scrutiny that identified multiple anomalies in the supporting data. The retraction notice states the concerns have been referred to the Iran Food and Drug Administration for an independent review, escalating the matter to a national regulatory body.

The retracted article, authored by Attar and colleagues, claimed to investigate the prevention of heart failure after a heart attack using an intracoronary infusion of mesenchymal stem cells. As part of its final decision, The BMJ also corrected the article's author list, removing two individuals who did not meet authorship criteria. This move underscores procedural flaws alongside the core questions about the trial's scientific validity. The original publication in October 2025 had positioned the research as a significant randomized clinical trial in a leading medical journal.

The retraction places intense scrutiny on the research team and the institutions involved, while the referral to Iran's FDA signals potential regulatory consequences. For the field of cardiac regenerative medicine, which has been marked by both promise and controversy, this incident represents a significant setback, eroding trust in published results and highlighting the critical role of post-publication peer review. It also raises immediate questions about the oversight of clinical trials and the verification of data in high-stakes medical research.